SAVO largely alleviated HFD‐induced hepatic steatosis, as evidenced by reduced hepatic triacylglycerol (TG) and total cholesterol (TC) levels, and reduced aspartate transferase (AST), alanine transaminase (ALT), TG, and TC levels in serum. The gene discussed is GPT; the disease is Hepatic steatosis.